The Economic Impact of COVID-19 on Healthcare Systems
A recently posted preprint systematic review in medRxiv has assessed the economic impact of the COVID-19 pandemic on healthcare systems [...]
Value in Health Regional Issues: Cost-Effectiveness of Novel Kidney Disease Biomarker Screening
IgA nephropathy (IgAN) is a leading cause of end-stage kidney disease across the world. A new paper in Value in [...]
New Value in Health Article: Limitations of Conventional Cost-Effectiveness Analysis and the ISPOR Value Flower
Conventional methods of cost-effectiveness often overlook key value elements for patients. The “ISPOR Value Flower,” introduced in the 2018 ISPOR [...]
Course Available: Introduction to Health Economics and Outcomes Research
A new course is being offered by ISPOR to teach clinicians the basics of health economics and outcomes research. Participants [...]
Interview: David Kim Talks about the Tufts Cost-Effectiveness Analyzer (CEA) Registry
Assistant professor David Kim speaks with Rachel Breslau about his role as program director of the Tufts cost-effectiveness analyzer (CEA) [...]
JAMA Report Investigates Cost-effectiveness Studies for Cancer Drugs
In a new article in the Journal of the American Medical Association, researchers Alyson Haslam, PhD, Mark P. Lythgoe, MD, [...]
Gene Therapy for Beta Thalassemia Gene Under ICER Assessment
A gene therapy for beta thalassemia will undergo ICER assessment for comparative clinical effectiveness and value. Betibeglogene autotemcel (Zynteglo/LentiGlobin) from [...]
Are Mammograms After 75 Worth It?
Uncertainty is building regarding the value of mammograms for breast cancer screening after 75 years of age according to a [...]
Establishing the Value of Next-Gen Sequencing
Next-generation sequencing (NGS) has been touted by some as the backbone of future precision medicine approaches. This technology could help [...]
ISPOR Boosts HEOR in Low & Middle-Income Countries
ISPOR pledged to promote HEOR efforts in low- to middle-income countries (LMICs) in its Strategic Plan 2024. LMICs often face [...]
PharmacoEconomics Article Authors Discuss 8 Recommendations for CEAs in Diagnostic Assessments
An article published in PharmacoEconomics details eight recommendations regarding how cost-effectiveness analyses (CEAs) are used in diagnostics. The researchers call [...]
ICER Releases Final Evidence Report for Hypertrophic Cardiomyopathy Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report for mavacamten, produced by MyoKardia and [...]
CEVR Leaders Publish NEJM Article on Determining Value Using Cost-Effectiveness Analyses
Peter Neumann, Sc.D., Joshua Cohen, Ph.D., and Daniel Ollendorf, Ph.D. of the Center for the Evaluation of Value and Risk [...]
ICER Releases Evidence Report on Mavacamten for Hypertrophic Cardiomyopathy Ahead of FDA Approval
The Institute for Clinical and Economic Review (ICER) has released its evidence report for mavacamten, used to treat hypertrophic cardiomyopathy [...]
New Drug Pricing Legislation Proposal Protects Small Biotech and Caps Prices
A new pricing policy would set limits on costs for seniors, protect small biotechs, and discount the prices of rapidly [...]
EQRx Partners With Two Payers to Reduce Drug Costs, Seeks Chinese Approval of Low Cost Oncology Drugs
EQRx has formed partnerships with two healthcare insurance companies to reach its ambitious goal of reducing drug costs. The company [...]
Cost-Effectiveness Analyses Fail to Consider Health Equity
Although an important tool in assessing a drug’s value, cost-effectiveness analyses (CEAs) fail to account for health equity. Important information [...]
Panalgo VP Discusses Changes to ICER’s Value Assessments Ahead of Mid-November Webinar
HealthEconomics.Com Founder and CEO Dr. Patti Peeples recently spoke with Panalgo’s Matt Sussman regarding changes to the value assessments carried [...]
Understanding the Power of Platform Trials
A recent Cytel blog post details the benefits of one category of the Master Protocol termed the platform trial, typically [...]
Pear Launches PDT Digest, Highlights the Power of Digital Tools in Improving Patient Outcomes and Reducing Costs
Pear Therapeutics recently launched the Prescription Digital Therapeutics (PDT) Digest, intended to showcase the value of digital tools in improving [...]
ICER’s Final Evidence Report for Two Myasthenia Gravis Therapies Now Available
The Institute for Clinical and Economic Review (ICER) has published its final evidence report for two drugs used to treat [...]
PRMA Consulting Leader Discusses the Rapidly Increasing Influence of ICER’s Value Access Frameworks
Senior Principal at PRMA Consulting Emily Coriale discusses how value assessments put forth by the Institute for Clinical and Economic [...]
ICER Releases Draft Evidence Report for AstraZeneca’s Asthma Drug
The Institute for Clinical and Economic Review (ICER) recently published its draft evidence report for asthma drug tezepelumab. The monoclonal [...]
New GRACE Cost-Effectiveness Tool Considers Patients’ Wishes and Improves Healthcare Decision-Making
The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) tool addresses some of the challenges associated with previous health economics and outcomes research (HEOR) [...]
Register Today for Upcoming Webinar on Using Automated Literature Review Tools to Improve Healthcare Economic Decision-Making
A webinar on using automated literature review tools to enhance healthcare cost-effectiveness analyses and other healthcare decisions will take place [...]